Avelumab: is it time to get excited?

Expert Rev Anticancer Ther. 2018 Sep;18(9):815-821. doi: 10.1080/14737140.2018.1493380. Epub 2018 Jul 2.
No abstract available

Keywords: Antibody-dependent cell-mediated cytotoxicity (ADCC); anti-PD-L1; avelumab; immune checkpoint blockade; immune checkpoint inhibitor; immunotherapy.

Publication types

  • Editorial

MeSH terms

  • Antibodies, Monoclonal / administration & dosage*
  • Antibodies, Monoclonal / pharmacology
  • Antibodies, Monoclonal, Humanized
  • Antineoplastic Agents, Immunological / administration & dosage
  • Antineoplastic Agents, Immunological / pharmacology
  • Humans
  • Immunotherapy / methods*
  • Neoplasms / drug therapy*
  • Neoplasms / immunology
  • Neoplasms / pathology

Substances

  • Antibodies, Monoclonal
  • Antibodies, Monoclonal, Humanized
  • Antineoplastic Agents, Immunological
  • avelumab